Home     Font Size: 1  2  3    Send to a Friend       search

2008 News

European Regulatory Agency Grants Orphan Status to Morphotek's Farletuzumab and MORAb-009

April 16, 2008

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Corporation of North America 201-746-2241...

+ Read the Article

Morphotek Signs Exclusive Licensing Agreement for Anti-Cancer Antibody

March 6, 2008

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Inc. 201-746-2241 judee_shuler@eisai.com ...

+ Read the Article

Morphotek Announces Collaborative Research Agreement with Ludwig Institute for Cancer Research

January 16, 2008

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Inc. 201-746-2241 judee_shuler@eisai.com ...

+ Read the Article

Morphotek Announces Agreement for the Development of Antibodies to Treat Prostate Cancer

January 9, 2008

Contact: Philip Sass Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Inc. 201-746-2241 judee_shuler@eisai.com Bryan ...

+ Read the Article

Morphotek Announces Initiation of MORAb-009 Phase II Study in First Line Treatment of Pancreatic Cancer

January 8, 2008

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Judee Shuler Eisai Inc. 201-746-2241 judee_shuler@eisai.com ...

+ Read the Article
Go to Page: 1

Results per page   10  25  50



©2005 Morphotek Inc. | 210 Welsh Pool Road | Exton, PA 19341 | (610) 423-6100                        Privacy Policy | Site Map | Contact Us